We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
- Authors
Cappuzzo, Federico; Ligorio, Claudia; Jänne, Pasi A; Toschi, Luca; Rossi, Elisa; Trisolini, Rocco; Paioli, Daniela; Holmes, Alison J; Magrini, Elisabetta; Finocchiaro, Giovanna; Bartolini, Stefania; Cancellieri, Alessandra; Ciardiello, Fortunato; Patelli, Marco; Crino, Lucio; Varella-Garcia, Marileila
- Abstract
In non-small-cell lung cancer (NSCLC), clinical and biologic predictors for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor sensitivity have been identified in retrospective studies, and there is urgent need to validate these results in prospective trials. The ONCOBELL trial is a prospective phase II study evaluating gefitinib sensitivity in NSCLC patients who never smoked or have increased EGFR gene copy number or activation of the antiapoptotic protein Akt.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 16, p2248
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.09.4300